Skip to main content
Premium Trial:

Request an Annual Quote

Bruker BioSciences Revenues Climb 16 Percent, Earnings Rise in Q4 of 2004

NEW YORK, March 3 (GenomeWeb News) - Bruker BioSciences yesterday reported increased revenues and earnings for the fourth quarter of 2004.

 

Revenues for the quarter were $85.8 million, 16 percent up from $73.7 million during the same period in 2003. Of these, Bruker Daltonics contributed $44.8 million, a 7-percent increase year over year, and Bruker AXS contributed $41.8 million, a 32-percent increase over the previous year's quarter.

 

Research and development expenses climbed to $11.7 million, up from $9.9 million during the year-ago quarter.

 

Bruker's net income for the quarter was $800,000, or $.01 per diluted share, up from $300,000, or $0 per diluted share, in the fourth quarter of 2003.

 

As of Dec. 31, Bruker had $78.8 million in cash and short-term investments.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.